Most patients with pancreatic ductal adenocarcinoma (PDAC) present with advanced-stage disease, for which systemic therapy is the mainstay, highlighting the need to identify therapeutically vulnerable molecular tumor subgroups. Homologous recombination deficiency (HRD), arising from germline or somatic alterations in...
J. Romero, Yi-Fan Wang, Edward Shanbedi et al.· Cancer Research· 0 citations
The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a multinational prospective longitudinal cohort study of participants with elevated heritable risk for pancreatic adenocarcinoma (PC). PRECEDE aims to support surveillance for high-risk individuals (HRIs) to inform clinical practice and public health p...
R. Wadlow, Samuel D. Newton, Jessica N. Everett et al.· Cancer Research· 0 citations
Despite the identification of several pancreatic ductal adenocarcinoma (PDAC) predisposition genes, more than 75% of familial pancreatic cancer (FPC) families remain genetically unexplained. To address this, we developed a systematic discovery pipeline focused on families with multiple affected individuals, leveragin...
Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.